Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > Only a corporate suit could call this merger a synergy...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by prophetoffactzon Jan 17, 2023 1:17pm
80 Views
Post# 35228492

RE:RE:RE:Only a corporate suit could call this merger a synergy...

RE:RE:RE:Only a corporate suit could call this merger a synergy...narmac, "Carina Biotech has taken precedence over Bioasis Tech this past year,,,it is very obvious!"

People have wondered.

Why not do a side-by-side analysis of BTI and Carina over the last year and get back to us.

1) Which company has raised the most money? (eg, potentially US$20 million for Biodexa vs. $X for Carina).

2) Which company has entered the biggest deals(eg. BTI: Crecense and Biodexa vs. X for Carina). Rathjen said she also presented another deal to regulators for BTI but was turned down.

3) Which company has signed the most evaluations including with the biggest names in biotech(eg. BTI: J&J, Neuramedy, Daiichi Sankyo, Ellipses, etc. vs. X for Carina). 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities